Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells.

Our Mission

Cellectis has 24 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. This enables us to develop a new generation of immunotherapy product candidates with additional safety and efficacy attributes and equip them to resist mechanisms that inhibit immune system activity.

Learn more


Cellectis is committed to good corporate governance, which promotes the long-term interests of shareholders, strengthens the Board of Directors and management accountability and helps build public trust in the Company. Our business practices foster our strong innovative and collaborative culture, which is committed to ethical behavior, accountability and transparency.

Learn more


We believe partnership is fundamental to achieving results. Our partners share the same objective to develop allogeneic cancer therapies that will benefit patients with unmet medical needs around the world.

Learn more

Corporate social responsibility

Cellectis is focused on addressing the medical and food needs of an ever-growing global population through the use of proprietary gene-editing technologies. By leveraging the expertise of our management, research and clinical teams, we believe we can make strong advancements in the immuno-oncology and plant sciences fields.

Cellectis’ Ethics Charter

By signing the Group’s Ethics Charter, each member of Cellectis commits to upholding its standards. For example, the values defended in this Charter cover the employee work conditions, as well as research objectives. Cellectis expects its associates, as well as its providers and subcontractors, to comply with this Charter in execution of their activities on a daily basis. They are also expected to respect human rights, labor rights, and the environment.